About Castle Biosciences
Castle Biosciences is a company based in Friendswood (United States) founded in 2008. Castle Biosciences has raised $61.97 million across 17 funding rounds from investors including SVB, BrightEdge and Industry Ventures. The company has 761 employees as of December 31, 2024. Castle Biosciences has completed 3 acquisitions, including AltheaDx, Castle Biosciences and Previse. Castle Biosciences offers products and services including DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and IDgenetix. Castle Biosciences operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Juno Therapeutics, DermTech and Unity Biotechnology, among others.
- Headquarter Friendswood, United States
- Employees 761 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Castle Biosciences, Inc.
-
Annual Revenue
$332.07 M (USD)51.09as on Dec 31, 2024
-
Net Profit
$18.25 M (USD)131.76as on Dec 31, 2024
-
EBITDA
$24.67 M (USD)144.33as on Dec 31, 2024
-
Total Equity Funding
$61.97 M (USD)
in 17 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Jul 29, 2019
-
Investors
SVB
& 4 more
-
Employee Count
761
as on Dec 31, 2024
-
Investments & Acquisitions
AltheaDx
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Castle Biosciences
Castle Biosciences is a publicly listed company on the NASDAQ with ticker symbol CSTL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Castle Biosciences
Castle Biosciences offers a comprehensive portfolio of products and services, including DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and IDgenetix.
Assesses risk of melanoma metastasis for treatment guidance.
Evaluates metastasis risk in squamous cell carcinoma patients.
Predicts progression risk for Barrett's esophagus to cancer.
Guides mental health medication based on genetic profiles.
People of Castle Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Castle Biosciences
Castle Biosciences has successfully raised a total of $61.97M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Castle Biosciences
Castle Biosciences has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, BrightEdge and Industry Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
BrightEdge is focused on impact investment in cancer care innovation.
|
Locked | Locked | Locked | |
|
Investments in private tech ecosystem are made by Industry Ventures.
|
Locked | Locked | Locked | |
|
Investments are focused on tech and life sciences startups.
|
Locked | Locked | Locked |
Investor details for Castle Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Castle Biosciences
Castle Biosciences has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include AltheaDx, Castle Biosciences and Previse.
Investment portfolio details for Castle Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cancer detection and prevention solutions are developed by Previse.
|
Locked | Locked | 2018 | Locked | |
|
Molecular diagnostics and biomarker discovery services are offered.
|
Locked | Locked | 2009 | Locked | |
|
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Castle Biosciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Castle Biosciences
Detailed financials for Castle Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Castle Biosciences Comparisons
Peer comparison for Castle Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Castle Biosciences
Castle Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Juno Therapeutics, DermTech and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Adhesive patch biopsies for skin cancer detection are provided.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of Castle Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Castle Biosciences
Complete news archive for Castle Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Castle Biosciences
Castle Biosciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Castle Biosciences is headquartered in Friendswood, United States. It is registered at Friendswood, Texas, United States.
Castle Biosciences is a funded company, having raised a total of $61.97M across 17 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Castle Biosciences is 761.
Annual revenue of Castle Biosciences is $332.07M as on Dec 31, 2024.
Castle Biosciences was founded in 2008 and is headquartered in Friendswood, United States. Operations focus on the biotechnology sector, where prognostic assays for conditions such as uveal melanoma, esophageal cancer, mesothelioma, cutaneous melanoma, and glioblastoma multiforme are developed. Additional tools like DecisionDx DiffDx-Melanoma for diagnosing melanocytic lesions are offered to support clinical decisions in oncology.
Castle Biosciences's top competitors include Juno Therapeutics, DermTech and Poseida Therapeutics.
Castle Biosciences offers DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and IDgenetix.
Yes, Castle Biosciences is publicly traded on NASDAQ under the ticker symbol CSTL.
Castle Biosciences has made 3 acquisitions, including AltheaDx, Castle Biosciences, and Previse.
Castle Biosciences has 5 investors. Key investors include SVB, BrightEdge, Industry Ventures, Health Quest Capital, and Mountain Group Partners.
The ticker symbol of Castle Biosciences is CSTL on NASDAQ.